SR9009 / SR9011
Metabolic Health · REV-ERB agonist / exercise mimetic
Tier D
High-risk evidence profile
Bottom line
Read Off Label grades SR9009 / SR9011 as D (2.9/10) based on preclinical evidence, unclear benefit magnitude, and a unknown-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
WADA coverage: Rev-erbalpha agonists, SR9009 and SR9011.
Studied, labeled, or reported-use context: No approved human dose — Research chemical; WADA S4 prohibited; not individualized guidance.
Frontier potential — editorial judgment, not evidence
This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.
What the ceiling rests on
REV-ERB agonists reported to produce "exercise-mimetic" effects in mice — increased mitochondrial content and running endurance without training — which is why the compound acquired its reputation.
Why it may not get there
A 2020 study found the headline endurance effects persisted in REV-ERB knockout mice, meaning the observed effects were substantially off-target rather than mechanism-driven. Oral bioavailability is very poor, so human exposure from oral dosing is minimal, and there is no human data at all. This is the clearest case in the database of a preclinical result whose stated mechanism did not hold up.
What would change this Resolution of the off-target findings; no human programme exists.
What the evidence says
WADA coverage: Rev-erbalpha agonists, SR9009 and SR9011. Added because these compounds are common in performance-enhancement marketplaces despite lacking approved human use.
Mechanism
REV-ERB agonists are marketed as endurance and fat-loss research chemicals based on circadian/metabolic signaling, but most claims are preclinical or gray-market extrapolation.
Studied, labeled, or reported dose & route
No approved human dose
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about SR9009 / SR9011's effects?
- Read Off Label rates the evidence for SR9009 / SR9011 as Preclinical and the benefit magnitude as unclear, producing an overall grade of D (2.9/10). WADA coverage: Rev-erbalpha agonists, SR9009 and SR9011.
- What safety findings are reported for SR9009 / SR9011?
- SR9009 / SR9011 has a unknown-high risk profile in the database. Unknown-High (limited human safety data, product-quality risk, metabolic/circadian uncertainty) Legal status: Research chemical; WADA S4 prohibited.
- What does the low Safety score for SR9009 / SR9011 represent?
- The Safety score is 3/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for SR9009 / SR9011?
- No approved human dose This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does SR9009 / SR9011 work?
- REV-ERB agonists are marketed as endurance and fat-loss research chemicals based on circadian/metabolic signaling, but most claims are preclinical or gray-market extrapolation.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.